Iterum Therapeutics Plc (ITRM)

$0.03 -0.04 (-57.39%)
Market Cap 1.60M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 65,735,500
Avg Vol 19,797,338
Day's Range N/A - N/A
Shares Out 53.29M
Stochastic %K 2%
Beta 2.96
Analysts Hold
Price Target $9.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
Amb8675309
Amb8675309 Aug. 24 at 4:55 AM
$ITRM it’s upsetting when anyone tries to make Corey Fishman out to be innocent- like I said last year the Maxim analyst told me that ITRM was a trifecta of things Wall Street did not give a 💩about.: women’s health, anti-infectives, and micro cap Biotech. All of that being said, CF knew what he was getting into. this was his first time as a CEO and so he made a lot of blunders . There was a time to have asked for capital- like when the share price hit $3/share on FDA approval- maybe that’s when you ask, not when it’s falling under a dollar. there were so many things he did poorly. I think he grabbed the molecule because he was greedy and if this ends up where we get any kind of payment back on our money, he’s going to be just fine, but all the people that rode this to the bottom, panicked and sold out on a liquidation news-don’t think he’ll lose any sleepover that. that’s why I think he’s a low integrity person , not a victim 
0 · Reply
CapitalismUSA
CapitalismUSA Aug. 24 at 12:50 AM
$ITRM Hoping we get some of our investment back and FishFuck finds his new home for life!!
1 · Reply
GatorMcKlusky
GatorMcKlusky Aug. 23 at 10:00 PM
$ITRM
0 · Reply
Amb8675309
Amb8675309 Aug. 23 at 7:40 PM
$ITRM @step05 you’re clearly an industry insider, but you’ve got some 🏀s to TRY to turn Corey Fishman into a victim. He chose this molecule- he never had sizable shares, but he was extolling all of us to agree to dilute ourselves. we are the collateral damage, not CF and you clearly missed that. Sheesh: saying it’s the molecule-come on. You have some nerve. THE MOMENT you go public and take shareholder money, you have a FIDUCIARY OBLIGATION to put the interests of the shareholders ahead of your own interests. Corey Fishman would never buy shares despite me begging him to do so. His launch was “for show”. He called in a favor re Coyne(salary?). CF burned 2Mil/month before he launched mid Q in Aug/25? And you have the gall to say it was the molecule. CF said yes to RLN terms- no CRL clause/8x CoC trigger? So you come onto this board and TRY to him into a victim? GTF outta here.
1 · Reply
Amb8675309
Amb8675309 Aug. 22 at 7:44 PM
$ITRM ST member since July 31/26-give me a break- sounds like another overpaid pharma douche justifying their salary- maybe it’s CF himself. My answer: It was CF’s own decision to license this molecule back in 2015- no one put a gun to his head. Trial design is on him, as CEO. Doing a PIPE below market, wasting 10 months before doing a half assed launch, with only 11 million in company coffers- all bad decisions Agreeing to Sarissa terms back in 2020-WTF whoever you really are, I live by #Ladderofaccountability CF needs to own his choices Fiduciary Obligation to shareholders- he seemed to forget about that one This guy tried to empty water off the titanic with a bucket. Will NEVER give that man a pass for making shareholders collateral damage on his self centered quest to be something more than a spreadsheet introvert and a supreme BS artist(@PomerantzLLC ready for round 2?) Trying to blame this FU on a pathogen-remember the disease class we are in- CF is a poster child:
0 · Reply
step05
step05 Aug. 22 at 6:33 PM
$ITRM Long play. Loser. Learner. The drag on Orlynvah is the results of the 2 clinical trials. The first trial proved it’s simply not a wonder drug. The second trail proved it’s simply not a wonder drug. The market and wise investors responded responsibly to the trial data. That is a good thing.. even though I personally lost money. It’s unfortunate that some spill a negative narrative about Itrm leadership. Bacteria is the villain and thief, not my fellow fighters. Lesson learned.
1 · Reply
Aircastles
Aircastles Aug. 22 at 4:02 AM
$ITRM I’m not saying anything will result from the below but a little something the coming week on this journey of nothing: Aug 25: important because it’s the deadline for anyone to file a due-diligence challenge to ORLYNVAH’s patent-term extension process. If no challenge filed, FDA’s regulatory-review-period determination can become final and the USPTO can move toward determining the final patent extension. Since Pfizer is seeking roughly five additional years of patent protection, clearing this hurdle could meaningfully strengthen ORLYNVAH’s value to a potential buyer. Aug 27: happy 5 month liquidation anniversary! Aug 31: important because the current ORLYNVAH copay-program terms tied to Alto Pharmacy are stated to expire on that date. It does not necessarily mean Alto stops distributing ORLYNVAH, but any renewal, replacement, disappearance, or broader website/distribution change around then could offer clues about how the asset is being managed during the Iterum liquidation.
3 · Reply
WaynD01
WaynD01 Aug. 22 at 2:59 AM
How did you hear about $SLS? I saw someone posted this in the $ITRM board in Oct-Nov 2024. Did the first purchase in December. Then continued increasing position by timing and obviously with some luck . Posted about this in $ZVRA board many times in the $1 s. So I am sure many benefitted from there. ( Btw, $ITRM went bankrupt, but made some good money off its drug approval and the subsequent down turn) .
4 · Reply
BTG007
BTG007 Aug. 22 at 2:19 AM
$ITRM a simple question: if we are FUKed, as a group of you keep saying, why do you keep checking back here? Can’t afford Netflix/HBO Max/Apple TV? There’s something strange about people that don’t believe in God, but they go to church every Sunday. 🤔
2 · Reply
GatorMcKlusky
GatorMcKlusky Aug. 22 at 1:46 AM
$ITRM Let us hope that Teneo is doing their due diligence and marketing their asset to Gosun. Gosun operates as a wholly-owned subsidiary and anti-infection business unit of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. And Sanjiu Medical is sitting on 9.61 billion Chinese Yuan or about $1.4 Billion USD. If they want Orlynvah it's theirs. MAKE THEM WANT IT.
0 · Reply
Latest News on ITRM
No data available.
Amb8675309
Amb8675309 Aug. 24 at 4:55 AM
$ITRM it’s upsetting when anyone tries to make Corey Fishman out to be innocent- like I said last year the Maxim analyst told me that ITRM was a trifecta of things Wall Street did not give a 💩about.: women’s health, anti-infectives, and micro cap Biotech. All of that being said, CF knew what he was getting into. this was his first time as a CEO and so he made a lot of blunders . There was a time to have asked for capital- like when the share price hit $3/share on FDA approval- maybe that’s when you ask, not when it’s falling under a dollar. there were so many things he did poorly. I think he grabbed the molecule because he was greedy and if this ends up where we get any kind of payment back on our money, he’s going to be just fine, but all the people that rode this to the bottom, panicked and sold out on a liquidation news-don’t think he’ll lose any sleepover that. that’s why I think he’s a low integrity person , not a victim 
0 · Reply
CapitalismUSA
CapitalismUSA Aug. 24 at 12:50 AM
$ITRM Hoping we get some of our investment back and FishFuck finds his new home for life!!
1 · Reply
GatorMcKlusky
GatorMcKlusky Aug. 23 at 10:00 PM
$ITRM
0 · Reply
Amb8675309
Amb8675309 Aug. 23 at 7:40 PM
$ITRM @step05 you’re clearly an industry insider, but you’ve got some 🏀s to TRY to turn Corey Fishman into a victim. He chose this molecule- he never had sizable shares, but he was extolling all of us to agree to dilute ourselves. we are the collateral damage, not CF and you clearly missed that. Sheesh: saying it’s the molecule-come on. You have some nerve. THE MOMENT you go public and take shareholder money, you have a FIDUCIARY OBLIGATION to put the interests of the shareholders ahead of your own interests. Corey Fishman would never buy shares despite me begging him to do so. His launch was “for show”. He called in a favor re Coyne(salary?). CF burned 2Mil/month before he launched mid Q in Aug/25? And you have the gall to say it was the molecule. CF said yes to RLN terms- no CRL clause/8x CoC trigger? So you come onto this board and TRY to him into a victim? GTF outta here.
1 · Reply
Amb8675309
Amb8675309 Aug. 22 at 7:44 PM
$ITRM ST member since July 31/26-give me a break- sounds like another overpaid pharma douche justifying their salary- maybe it’s CF himself. My answer: It was CF’s own decision to license this molecule back in 2015- no one put a gun to his head. Trial design is on him, as CEO. Doing a PIPE below market, wasting 10 months before doing a half assed launch, with only 11 million in company coffers- all bad decisions Agreeing to Sarissa terms back in 2020-WTF whoever you really are, I live by #Ladderofaccountability CF needs to own his choices Fiduciary Obligation to shareholders- he seemed to forget about that one This guy tried to empty water off the titanic with a bucket. Will NEVER give that man a pass for making shareholders collateral damage on his self centered quest to be something more than a spreadsheet introvert and a supreme BS artist(@PomerantzLLC ready for round 2?) Trying to blame this FU on a pathogen-remember the disease class we are in- CF is a poster child:
0 · Reply
step05
step05 Aug. 22 at 6:33 PM
$ITRM Long play. Loser. Learner. The drag on Orlynvah is the results of the 2 clinical trials. The first trial proved it’s simply not a wonder drug. The second trail proved it’s simply not a wonder drug. The market and wise investors responded responsibly to the trial data. That is a good thing.. even though I personally lost money. It’s unfortunate that some spill a negative narrative about Itrm leadership. Bacteria is the villain and thief, not my fellow fighters. Lesson learned.
1 · Reply
Aircastles
Aircastles Aug. 22 at 4:02 AM
$ITRM I’m not saying anything will result from the below but a little something the coming week on this journey of nothing: Aug 25: important because it’s the deadline for anyone to file a due-diligence challenge to ORLYNVAH’s patent-term extension process. If no challenge filed, FDA’s regulatory-review-period determination can become final and the USPTO can move toward determining the final patent extension. Since Pfizer is seeking roughly five additional years of patent protection, clearing this hurdle could meaningfully strengthen ORLYNVAH’s value to a potential buyer. Aug 27: happy 5 month liquidation anniversary! Aug 31: important because the current ORLYNVAH copay-program terms tied to Alto Pharmacy are stated to expire on that date. It does not necessarily mean Alto stops distributing ORLYNVAH, but any renewal, replacement, disappearance, or broader website/distribution change around then could offer clues about how the asset is being managed during the Iterum liquidation.
3 · Reply
WaynD01
WaynD01 Aug. 22 at 2:59 AM
How did you hear about $SLS? I saw someone posted this in the $ITRM board in Oct-Nov 2024. Did the first purchase in December. Then continued increasing position by timing and obviously with some luck . Posted about this in $ZVRA board many times in the $1 s. So I am sure many benefitted from there. ( Btw, $ITRM went bankrupt, but made some good money off its drug approval and the subsequent down turn) .
4 · Reply
BTG007
BTG007 Aug. 22 at 2:19 AM
$ITRM a simple question: if we are FUKed, as a group of you keep saying, why do you keep checking back here? Can’t afford Netflix/HBO Max/Apple TV? There’s something strange about people that don’t believe in God, but they go to church every Sunday. 🤔
2 · Reply
GatorMcKlusky
GatorMcKlusky Aug. 22 at 1:46 AM
$ITRM Let us hope that Teneo is doing their due diligence and marketing their asset to Gosun. Gosun operates as a wholly-owned subsidiary and anti-infection business unit of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. And Sanjiu Medical is sitting on 9.61 billion Chinese Yuan or about $1.4 Billion USD. If they want Orlynvah it's theirs. MAKE THEM WANT IT.
0 · Reply
XJCX
XJCX Aug. 21 at 11:46 PM
$ITRM The Chinese route... a buyer like Gosun values what Orlynvah represents as a technological asset and as a gateway to a much broader family...
1 · Reply
GatorMcKlusky
GatorMcKlusky Aug. 21 at 7:59 PM
$ITRM I'm showing 2280 volume today. Looks like they moved the decimal further to the right. My 1.80 total is now worth 0.18. Not like that matters. Only thing that matters is hurdling that debt stack by a good margin.
1 · Reply
Toptopy
Toptopy Aug. 21 at 6:16 PM
$ITRM
1 · Reply
roseohara44
roseohara44 Aug. 21 at 4:27 PM
$ITRM could somebody translate that page
4 · Reply
EarlyRetirement0077
EarlyRetirement0077 Aug. 21 at 1:55 PM
$ITRM I can’t take it anymore guys just give me the good news
2 · Reply
DollerADay
DollerADay Aug. 21 at 1:42 PM
$ITRM The interesting part was this came out 1 day after liquidation on their 255 page annual report. Sulopenem was mentioned multiple times. Chinese antibacterial intelligence experts already designated it globally commercially relevant for UTI, Intra Abdominal infection, community acquired pneumonia already. This is the tip of the iceberg if you have been doing your homework. What's coming will be unlike anything you will ever see again...
1 · Reply
XJCX
XJCX Aug. 21 at 11:29 AM
$ITRM
0 · Reply
XJCX
XJCX Aug. 21 at 11:15 AM
$ITRM https://www.shionogi.com/global/en/news/2026/01/e20260108.html
1 · Reply
XJCX
XJCX Aug. 21 at 11:13 AM
$ITRM https://www.maruho.co.jp/english/information/20251117.html
0 · Reply
Toptopy
Toptopy Aug. 21 at 10:17 AM
$ITRM https://m.familydoctor.cn/news/kangshengsu-naiyaoxing-riyiyanzhong-qiewu-yanwu-xinyao-yanfa-402261.html
1 · Reply
Brokensmoke
Brokensmoke Aug. 21 at 8:33 AM
$ITRM
0 · Reply
CapitalismUSA
CapitalismUSA Aug. 21 at 12:54 AM
$ITRM Predicting October ASA. $5-6 per share
1 · Reply